NCT04354324View on ClinicalTrials.gov

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

NARecruitingINTERVENTIONAL

Enrollment

254

Participants

Timeline

Start Date

April 20, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Papillary Thyroid Cancer

Interventions

DRUG

Radioiodine

The test group: low dosage (30mci). The control group: high dosage (100mci).

Trial Locations (1)

510282

RECRUITING

Huijuan Feng, Guangzhou

All Listed Sponsors

lead

Zhujiang Hospital

OTHER